Similar methodology questions are raised about the "science" behind Medscape's Quadrivalent HPV Vaccine May Be Effective in Women 24 to 45 Years Old CME in the October 10 Lancet.
Why did Munoz et al exclude women "with pre-existing infections and women who do not complete the full course of the vaccine," ask six researchers with US National Cancer Institute. Is this also a sample of convenience? And why was "infection of 6 month duration or longer" used as an endpoint for showing a public health cancer benefit asks a different set of researchers, Stefanie Schenk and Jutta Halbekath from Berlin--when no "differentiation" between infection and cancer is given?
Clearly the letter writers need to do their CMEs.
(Note: You can view every article as one long page if you sign up as an Advocate Member, or higher).
